HSV thymidine kinase gene therapy

Drug Profile

HSV thymidine kinase gene therapy

Alternative Names: Retrovector™

Latest Information Update: 22 Jul 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AVAX Technologies; Edison Biotechnology Institute; Novartis; Scientific Institute San Raffaele; Universite Pierre et Marie Curie
  • Developer AVAX Technologies; Aventis Gencell; Edison Biotechnology Institute; Human Gene Therapy Research Institute (Des Moines); Novartis; Scientific Institute San Raffaele
  • Class Gene therapies
  • Mechanism of Action Thymidine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Brain cancer; Glioma; Graft-versus-host disease; Leukaemia; Liver cancer; Lymphoma; Malignant melanoma; Mesothelioma; Multiple myeloma; Ovarian cancer; Renal cancer

Most Recent Events

  • 20 Apr 2006 Chiron Corporation has been acquired and merged into Novartis
  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
  • 20 May 2002 Interneuron Pharmaceuticals is now called Indevus Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top